Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead candidate. ZEPHYR Phase 2 in schizophrenia (300 participants) reached target enrollment Apr 2026; topline expected Q3 2026. VISTA Phase 2 in ADP topline expected H2 2027. Fast Track granted Dec 2025 for hallucinations and delusions associated with ADP.
ML-004
Phase 2 · ActiveModality: 5-HT1B/1D agonist
Target 5-HT1B/1D
Indications
Social communication deficit and/or irritability in autism spectrum disorder (IRIS Phase 2)(Phase 2)
Status note Second clinical-stage candidate; topline results from the IRIS Phase 2 trial announced Jun 2026.
Partnerships NeuroSolis, Inc.: asset purchase agreement for M1/M4 agonist molecules and associated IP (contingent issuance of up to 62,083 shares)
Indications
Neuropsychiatric conditions(Preclinical)
Status note Next-generation M1/M4 muscarinic agonist program; preclinical in vitro/in vivo studies ongoing.
ML-021
Preclinical · ActiveModality: M4 antagonist
Target M4
Partnerships Michael J. Fox Foundation: research grants (Feb 2020-Aug 2022)
Indications
Motor deficits in Parkinson's disease(Preclinical)
Status note Preclinical candidate finalization for IND-enabling studies.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.